Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium Business Wire - Thu Feb 5, 6:00PM CST

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months

PLSE : 23.92 (-1.20%)
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026 Business Wire - Wed Feb 4, 3:05PM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 23.92 (-1.20%)
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium Business Wire - Tue Feb 3, 6:00AM CST

nPulse Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission

PLSE : 23.92 (-1.20%)
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors Business Wire - Fri Jan 9, 6:00AM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

HYPR : 1.0900 (-4.39%)
OFIX : 13.37 (+2.37%)
SPNC : 38.45 (unch)
AVNS : 14.72 (+3.30%)
PLSE : 23.92 (-1.20%)
SWAV : 334.75 (-0.02%)
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium Business Wire - Tue Jan 6, 6:00AM CST

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 23.92 (-1.20%)
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire - Mon Dec 29, 2025

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 23.92 (-1.20%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Dec 19, 2025

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 23.92 (-1.20%)
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation Business Wire - Thu Dec 18, 2025

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 23.92 (-1.20%)
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology Business Wire - Tue Dec 9, 2025

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond...

PLSE : 23.92 (-1.20%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Nov 21, 2025

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 23.92 (-1.20%)

Barchart Exclusives

This Is the Top-Rated Dividend Stock to Buy in February 2026 Barchart - Tue Feb 10, 6:30PM CST
CMCL’s low payout ratio, hedged $3,500‑floor gold pricing, and 56% implied upside from its lone “Strong Buy” target make it an attractive small‑cap dividend grower for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot